The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage

Objective: To evaluate whether receipt of 17α-hydroxyprogesterone caproate within 7 days of delivery is associated with increased risk of postpartum hemorrhage. Study Design: This was a retrospective cohort study of women who were receiving 17α-hydroxyprogesterone caproate for preterm birth prevention and delivered between 2010 and 2014. Women were dichotomized by whether a dose of 17α-hydroxyprogesterone caproate was administered within 7 days of delivery. Demographic and clinical characteristics were examined, including obstetric history and details of 17α-hydroxyprogesterone caproate receipt. Bivariable analyses were used to compare the frequency of postpartum hemorrhage in women stratified by 17α-hydroxyprogesterone caproate receipt within 7 days of delivery. Multivariable analysis was used to adjust for potential confounders. Results: Of 221 women who met inclusion criteria, 93 (42%) received 17α-hydroxyprogesterone caproate within 7 days of delivery and 18 (7.8%) experienced a postpartum hemorrhage. No differences were observed in the frequency of postpartum hemorrhage between women who did and did not deliver within 7 days of 17α-hydroxyprogesterone caproate injection (9.7% vs 7.0%, P=.478). These findings persisted after adjusting for potential confounders (adjusted odds ratio for postpartum hemorrhage, 2.9; 95% confidence interval, 0.5–15.8). Conclusion: Recent receipt of 17α-hydroxyprogesterone caproate for prevention of recurrent preterm birth is not associated with risk of postpartum hemorrhage.